Half-life extension technologies for haemostatic agents

• Published in: Thrombosis and haemostasis Vol. 113; no. 1; p. 165
• Main Author: Mannucci, Pier Mannuccio
• Format: Journal Article
• Language: English
• Published: Germany 01.01.2015
• Subjects: Animals; Blood Coagulation Factors - administration & dosage; Blood Coagulation Factors - adverse effects; Blood Coagulation Factors - pharmacokinetics; Coagulants - administration & dosage; Coagulants - adverse effects; Coagulants - pharmacokinetics; Drug Administration Schedule; Half-Life; Hemophilia A - blood; Hemophilia A - diagnosis; Hemophilia A - drug therapy; Hemophilia B - blood; Hemophilia B - diagnosis; Hemophilia B - drug therapy; Hemostasis - drug effects; Humans; Infusions, Intravenous; Protein Stability; Proteolysis; Recombinant Fusion Proteins - administration & dosage; Recombinant Fusion Proteins - adverse effects; Recombinant Fusion Proteins - pharmacokinetics; Treatment Outcome; prolonged half-life; coagulation factors; Haemophilia
• ISSN: 0340-6245
• DOI: 10.1160/TH14-04-0332

The use of plasma-derived and recombinant coagulation factors for the treatment of haemophilia A and B is well established and permits patients to live a relatively normal life. In order to improve treatment options, several products are in development, which have a prolonged duration of action, thus enabling less frequent prophylactic dosing and aiming to reduce the burden of treatment. Several innovative approaches are being pursued to extend the half-life of factor VIIa, factor VIII and factor IX, utilising technologies such as Fc fusion, recombinant albumin fusion and addition of polyethyleneglycol (PEG) (PEGylation). These methods prolong the time in the circulation by reducing degradation and elimination. This review summarises the technologies and products in development and their stages of development, and also discusses their pros and cons.